Find a lawyerOur capabilitiesYour career
Locations
Our capabilities
News

Select language:

Locations
Our capabilities
News

Select language:

hamburger menu showcase image
  1. Our thinking
  2. Blogs
  3. A Fresh Take
  4. Life Sciences Round Up – Q3 2026
4MIN

Life Sciences Round Up – Q3 2026

Subscribe
Oct 15 2026

Q3 2026 was a busy one for the life sciences sector, with drug pricing, AI and antitrust all in the headlines. Here are the top issues and trends we’ve been tracking.

MFN Pricing Updates

The Trump administration’s push on MFN pricing reached deeper into the market. On August 31, the White House announced MFN agreements with nine mid-sized manufacturers, bringing the total to 26 companies, reportedly covering about 89% of the branded drug market. Although confidential, experts expect the deals to bring tariff and GLOBE/GUARD relief (discussed in part below) in exchange for certain MFN and manufacturing commitments.

Meanwhile, CMS announced the finalization of the GLOBE Model, which brings international reference pricing into Medicare Part B for certain Medicare beneficiaries. The final version of GLOBE, however, should have significantly less impact than originally proposed, as CMS now expects the program to produce only $440 million in savings (a decline of more than 96% as compared to the initially-proposed rule) after narrowing the program. Further, experts expect GLOBE to face substantial legal scrutiny—Pharmaceutical Research and Manufacturers of America (PhRMA) has already filed suit against CMS in the D.C. District Court, alleging the agency exceeded its statutory authority and violated the Constitution in finalizing the model.

Nevertheless, the considerations we flagged in our Q1 2026 Round Up remain pressing for dealmakers.

AI‑enabled R&D Innovation

Life sciences companies continue partnering with AI companies to expedite early-stage discovery work, reduce its cost, and hopefully increase the probability of success.

The AI market continues to mature at a rapid pace, and we have noticed a few AI-specific deal terms emerge in our own practice, particularly in license-based discovery collaborations: data licenses to train and develop new AI models, covenants regarding human inventorship, and partners’ right to access and use the underlying AI platform (and associated guardrails). 

A second, lighter model is also gaining traction: AI-enabled analysis as a service, where the AI company runs its platform over the biotech's own pre-clinical data under a master services agreement to deliver a report rather than a candidate, sometimes with fees settled partly in listed shares (raising capital markets questions around pricing and market abuse). 

Risk allocation centers on process-based standards paired with a reliability benchmark that asks not whether the output was "correct," but whether a competent independent expert reviewing the same data would have reached materially the same conclusion. Key sticking points include whether liability caps should cover misdirected R&D spend and whether customers can secure ownership of all data-derived outputs against providers' efforts to retain reusable platform improvements.

As more and more of these AI collaborations progress from early-stage discovery into later stage development, a larger body of clinical data will be generated on AI-discovered compounds. If these trials are more successful compared to those investigating compounds discovered from more traditional R&D technologies, the negotiating dynamics between “traditional” pharmaceutical companies and AI-drug discovery companies may be altered, with the latter potentially having greater success in pushing for enhanced economics (compared to the mixed results we initially observed in our Q1 2026 Round Up). Whatever the outcome, we expect these upcoming clinical trial results to be priced into future AI drug discovery deals.

On the topic of trends in biopharma innovation, be sure to check out our key takeaways from our participation in the Biotech Week Boston LSX USA Congress panel on “Shaping the Future of Biopharma: Global Investment and Innovation in Established & Emerging Markets”.

Antitrust Developments

Pipeline pressure for pharma companies is starting to change what M&A deals they are willing to consider. For example, we are seeing transactions where the buyer has a marketed product and the target has a pipeline asset for the same indication. In situations where the buyer’s patent protection is expiring, the antitrust risk can be lower, which opens the door to deals that would previously have been off the table.

In the U.S., the FTC continues to sharpen its focus on patent violations and the antitrust implications of those violations. Most recently, in August 2026, the FTC filed an amicus brief with the Fourth Circuit in CareFirst v. Amgen, signaling that acquiring a patent application is the same as acquiring an issued patent under U.S. antitrust laws, and any acquisitions that may arguably be undertaken to prolong drug monopolies and block biologic competition will face heightened antitrust oversight.

And, over in the UK, the Court of Appeal recently upheld the Competition Appeal Tribunal’s judgment that certain manufacturers charged excessive and unfair prices for immediate-release hydrocortisone tablets. Prices had risen by more than 10,000% after the manufacturer had “de-branded” the drug and took it outside the NHS Pharmaceutical Price Regulation Scheme. The decision highlights there is no free pass for steep price hikes, particularly following de-branding, absent demonstrable cost increases, innovation, or investment.

* * *

Deal momentum remains strong heading into year-end, both on the licensing and the M&A front. We look forward to seeing which make it across the finish line to announce at JPM!

Many thanks to the Freshfields lawyers who contributed to this piece.

To receive the latest insights on US legal developments, subscribe to the Freshfields A Fresh Take Blog.

Tags

antitrust and competitionartificial intelligencelife sciences

Authors

Boston

Jimmy Cao

Associate
San Francisco

Yungjee Kim

Associate

Co-Authors

Washington, DC

Kristen Olvera Riemenschneider

Partner, Global Co-Head of Life Sciences
Boston

Andrea Devoe

Partner
New York

Jeff Jay

Partner
Latest Insights

Latest Insights

NAVIGATE TO
About usLocations and officesYour careerOur thinkingOur capabilitiesNews
CONNECT
Find a lawyerAlumniContact us
NEED HELP
Fraud and scamsComplaintsTerms and conditions
LEGAL
AccessibilityCookiesLegal noticesTransparency in supply chains statementResponsible procurementPrivacy

Select language:
Select language:
© 2026 Freshfields. Attorney Advertising: prior results do not guarantee a similar outcome